Beijing Beilu Pharmaceutical Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Beijing Beilu Pharmaceutical Company Limited with three other
companies in this sector in China:
Lanzhou Foci Pharmaceutical Co Limited
sales of 501.14 million Chinese Renmimbi [US$78.50 million]
of which 100%
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
(497.69 million Chinese Renmimbi [US$77.96 million]
Coland Holdings Limited
(586.59 million Chinese Renmimbi [US$91.88 million]
of which 100%
was Medical Services).
Beijing Beilu Pharmaceutical Company Limited reported sales of 522.54 million Chinese Renmimbi (US$81.85 million)
December of 2017.
increase of 4.8%
versus 2016, when the company's sales were 498.81 million Chinese Renmimbi.
Sales at Beijing Beilu Pharmaceutical Company Limited have increased during each of the previous five years
(and since 2012, sales have increased a total of 92%).
Sales of Pharmaceutical Sales saw an increase
that was more than double the company's growth rate: sales were up
10.6% in 2017, from
469.91 million Chinese Renmimbi to 519.81 million Chinese Renmimbi.
Not all segments of Beijing Beilu Pharmaceutical Company Limited experienced an increase in sales in 2017:
sales of Other Operation fell 42.7% to 2.72 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).